PUBLIC COMPANY
save$QTTBQ32 Bio Inc.
$QTTB15.39+2.06%Waltham, MA, USupdated 18d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
- phase2A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
- phase2Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (3)
- Feb 24, 26grantViolette Shelia M. · Chief Scientific Officer37,500 sh
- Feb 24, 26grantMorrison Jodie Pope · CEO132,000 sh
- Feb 24, 26grantKalowski Lee · CFO and President53,250 sh
🐶 Hiring Signal
News
- Erasca's $550M offering; Summit sells an antibioticPlus, news about subcutaneous Leqembi, WuXi AppTec and Q32 Bio. 📊 Erasca targets $550M for KRAS drugs: The biotech's public offering came after it shared a small ...endpoints · 1mo ago
- Q32 bounces back to claim study success for alopecia drugNearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations.biopharma_dive · 1mo ago
- Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trialPlus, news about Insilico, Ipsen, Q32 Bio, GSK’s Jemperli, Drug Farm and Padcev. ❌ FDA rejects Tris Pharma’s narcolepsy drug: Its rejection letter said that “additional information will be necessar…endpoints · 1mo ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that